European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy
-
Published:2024-05
Issue:
Volume:194
Page:110215
-
ISSN:0167-8140
-
Container-title:Radiotherapy and Oncology
-
language:en
-
Short-container-title:Radiotherapy and Oncology
Author:
Scharl Sophia, Zamboglou Constantinos, Strouthos Iosif, Farolfi Andrea, Serani FrancescaORCID, Koerber Stefan A., Debus Jürgen, Peeken Jan C., Vogel Marco M.E., Kroeze Stephanie G.C., Guckenberger MatthiasORCID, Krafcsik Manuel, Hruby George, Emmett Louise, Schmidt-Hegemann Nina-Sophie, Trapp ChristianORCID, Spohn Simon K.B., Henkenberens Christoph, Mayer BenjaminORCID, Shelan MohamedORCID, Aebersold Daniel M., Thamm ReinhardORCID, Wiegel Thomas
Reference23 articles.
1. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence;Pompe;Prostate,2018 2. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival;Bartkowiak;Radiother Oncol,2016 3. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival;Bartkowiak;Acta Oncol,2018 4. Tilki D, Preisser F, Thamm R, Pompe RS, Chun FK-H, Graefen M, et al. Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. Cancers (Basel) 2022;14:740. 10.3390/cancers14030740. 5. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death;Tilki;J Clin Oncol,2023
|
|